Almirall (ALM) AI Stock Analysis

• Market Cap: €2.61B
• Dividend Yield: 1.36%
• Average Volume (3M): 106.20K
• Price to Earnings (P/E): 121.8
• Beta (1Y): 0.45
• Revenue Growth: 13.32%
• EPS Growth: N/A
• Country: ES
• Employees: 2,026
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.14
• Shares Outstanding: 214,785,200
• 10 Day Avg. Volume: 134,753
• 30 Day Avg. Volume: 106,204
• PEG Ratio: -1.38
• Price to Book (P/B): 1.17
• Price to Sales (P/S): 1.77
• P/FCF Ratio: -2.62K
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €15.10
• Price Target Upside: 30.40% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 61 Neutral
• Price Target: €12.50 ▲(7.94% Upside)

Almirall's overall stock score is primarily influenced by its stable financial position and strong technical indicators. However, the high P/E ratio suggests overvaluation, which is a significant risk. The lack of earnings call data and corporate events means these factors do not impact the score.

Almirall Business Overview & Revenue Model

Company Description

Almirall, S.A., a biopharmaceutical company, engages in the research, development, manufacture, and sale of skin-health related medicines in Europe, the United States, and internationally. The company offers its products for dermatological diseases comprising actinic keratosis, atopic dermatitis, androgenic alopecia, psoriasis, onychomycosis, oncodermatology, acne, and orphan indications, as well as for cardiovascular, musculo-skeletal, respiratory, and nervous system; alimentary tract and metabolism; antiinfectives for systemic use; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. Its products include Ilumetri, Solaraze, Actikerall, Ciclopoli, Skilarence, Aczone, Decoderm, Cordran Tape, Azelex, Klisyri, Tazorac, Seysara, Veltin, Almax, Ebastel, Sativex, Crestor, and Efficib/Tesavel. Almirall, S.A. has collaboration and partnership agreements with Tyris Therapeutics, BIOMAP, the University of Dundee, Kaken Pharmaceutical Co Ltd., Ichnos Sciences Inc., the University Carlos III Madrid and MEDINA Foundation, 23andMe, Inc., HitGen Ltd., WuXi Biologics, Eli Lilly and Company, and Athenex, Inc. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.

How the Company Makes Money

Almirall generates revenue primarily through the sale of its pharmaceutical products, with key revenue streams coming from its portfolio of prescription medications in dermatology and other therapeutic areas. The company benefits from a combination of direct sales and partnerships with other pharmaceutical firms to expand its market reach. Additionally, Almirall engages in licensing agreements, enabling it to earn royalties from its products while also collaborating with research and development partners for new therapeutic innovations. The success of its revenue model is bolstered by strategic collaborations, access to new markets, and a focus on high-demand treatments, allowing Almirall to capitalize on growing healthcare needs.

Almirall Financial Statement Overview

Summary

Almirall exhibits a stable financial position with strong gross margins and manageable debt levels. However, profitability remains a concern with low net profit margins and negative free cash flow growth. The company needs to focus on improving cash flow generation and enhancing shareholder returns to strengthen its financial health.

Income Statement

Almirall's income statement shows moderate growth and profitability. The TTM revenue growth rate of 2.54% indicates steady progress, although it has slowed compared to previous years. Gross profit margins remain strong at 78.09%, reflecting efficient cost management. However, net profit margins are low at 2.03%, suggesting limited profitability. The EBIT and EBITDA margins are improving, indicating better operational efficiency.

Balance Sheet

The balance sheet reflects a stable financial position with a debt-to-equity ratio of 0.28, indicating manageable leverage. The return on equity is low at 1.44%, suggesting limited returns for shareholders. The equity ratio of 63.41% demonstrates a solid capital structure with a significant portion of assets financed by equity.

Cash Flow

Cash flow analysis reveals challenges, with negative free cash flow growth of -18.03% in the TTM period. The operating cash flow to net income ratio of 0.51 indicates moderate cash generation relative to net income. However, the negative free cash flow to net income ratio highlights cash flow constraints, potentially impacting future investments.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.05B	985.72M	894.52M	863.25M	827.20M	1.61B
Gross Profit	819.14M	767.68M	577.12M	680.78M	655.61M	1.44B
EBITDA	200.60M	173.80M	122.51M	165.07M	132.34M	220.87M
Net Income	21.34M	10.15M	-38.47M	4.28M	-40.86M	74.28M
Balance Sheet
Total Assets	2.31B	2.40B	2.37B	2.15B	2.14B	2.29B
Cash, Cash Equivalents and Short-Term Investments	323.23M	377.30M	388.09M	248.82M	207.39M	165.67M
Total Debt	404.80M	408.81M	403.25M	403.88M	396.11M	496.98M
Total Liabilities	844.82M	908.28M	911.59M	828.98M	855.71M	988.15M
Stockholders Equity	1.46B	1.49B	1.46B	1.32B	1.29B	1.30B
Cash Flow
Free Cash Flow	-86.66M	-664.00K	-65.82M	38.62M	162.70M	88.24M
Operating Cash Flow	152.00M	160.77M	93.48M	155.10M	233.85M	164.76M
Investing Cash Flow	-83.34M	-140.04M	-122.56M	-68.54M	-57.26M	-75.52M
Financing Cash Flow	-52.94M	-31.58M	168.21M	-45.12M	-134.88M	-40.87M

Almirall Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 11.58
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ES:ALM, the sentiment is Neutral. The current price of 11.58 is below the 20-day moving average (MA) of 12.19, below the 50-day MA of 11.73, and above the 200-day MA of 10.57, indicating a neutral trend. The MACD of 0.05 indicates Positive momentum. The RSI at 37.72 is Neutral, neither overbought nor oversold. The STOCH value of 7.58 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ES:ALM.

Almirall Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FAE	77 Outperform	€1.37B	13.00	14.89%	4.07%	11.04%	8.29%
RJF	65 Neutral	€234.40M	52.66	2.03%	1.74%	-1.19%	-54.66%
ROVI	65 Neutral	€2.98B	22.67	20.70%	1.70%	-9.39%	-25.92%
ALM	61 Neutral	€2.61B	121.80	1.45%	1.36%	13.32%	―
PHM	56 Neutral	$1.31B	38.26	17.22%	1.12%	7.35%	5375.64%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%